OBJECTIVES: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS: ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5 Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5 Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models. RESULTS: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5 Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95% confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191]. CONCLUSION: The GRK5 Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.
OBJECTIVES: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS:ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models. RESULTS: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95% confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191]. CONCLUSION: The GRK5Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.
Authors: Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler Journal: Science Date: 2002-05-23 Impact factor: 47.728
Authors: Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren Journal: Lancet Date: 2005 Sep 10-16 Impact factor: 79.321
Authors: M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245
Authors: Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley Journal: JAMA Date: 2003-12-03 Impact factor: 56.272
Authors: Daniel Kurnik; Andrew J Cunningham; Gbenga G Sofowora; Utkarsh Kohli; Chun Li; Eitan A Friedman; Mordechai Muszkat; Usha B Menon; Alastair Jj Wood; C Michael Stein Journal: Pharmacogenomics Date: 2009-10 Impact factor: 2.533
Authors: Amber L Beitelshees; Yan Gong; Danxin Wang; Nicholas J Schork; Rhonda M Cooper-Dehoff; Taimour Y Langaee; Mark D Shriver; Wolfgang Sadee; Harm J Knot; Carl J Pepine; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2007-09 Impact factor: 2.089
Authors: Mihai V Podgoreanu; Joseph P Mathew; Miklos D Kertai; Yen-Wei Li; Yi-Ju Li; Svati H Shah; William E Kraus; Manuel L Fontes; Mark Stafford-Smith; Mark F Newman Journal: Circ Cardiovasc Genet Date: 2014-07-21
Authors: Martina Chittani; Roberta Zaninello; Chiara Lanzani; Francesca Frau; Maria F Ortu; Erika Salvi; Giovanni Fresu; Lorena Citterio; Daniele Braga; Daniela A Piras; Simona Delli Carpini; Dinesh Velayutham; Marco Simonini; Giuseppe Argiolas; Simona Pozzoli; Chiara Troffa; Valeria Glorioso; Kimmo K Kontula; Timo P Hiltunen; Kati M Donner; Stephen T Turner; Eric Boerwinkle; Arlene B Chapman; Sandosh Padmanabhan; Anna F Dominiczak; Olle Melander; Julie A Johnson; Rhonda M Cooper-Dehoff; Yan Gong; Natalia V Rivera; Gianluigi Condorelli; Bruno Trimarco; Paolo Manunta; Daniele Cusi; Nicola Glorioso; Cristina Barlassina Journal: J Hypertens Date: 2015-06 Impact factor: 4.844